One of the most recent findings suggested that high levels of tumor-infiltrating lymphocytes (TILs) are associated with improved patients’ outcomes in both triple negative and HER2+ve breast cancer, whereas the role of TILs in Luminal cancer remains unknown. The gene discussed is ERBB2; the disease is neoplasm.